Related Experiment Video
Updated: Jul 3, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy
Ilya V Ulasov1, Matthew A Tyler, Angel A Rivera
1The Brain Tumor Center, The University of Chicago, Chicago, Illinois 60637, USA.
Abstract:
Malignant glioma, in particular glioblastoma multiforme (GBM), represents one of the most devastating cancers currently known and existing treatment regimens do little to change patient prognosis. Conditionally replicating adenoviral vectors (CRAds) represent attractive experimental anti-cancer agents with potential for clinical application. However, early protein products of the wild type adenovirus backbone--such as E1A--limit CRAds' replicative specificity. In this study, we evaluated the oncolytic potency and specificity of CRAds in which p300/CPB and/or pRb binding capacities of E1A were ablated to reduce non-specific replicative cytolysis. In vitro cytopathic assays, quantitative PCR analysis, Western blot, and flow cytometry studies demonstrate the superior anti-glioma efficacy of a double-mutated CRAd, Ad2/24CMV, which harbors mutations that reduce E1A binding to p300/CPB and pRb. When compared to its single-mutated and wild type counterparts, Ad2/24CMV demonstrated attenuated replication and cytotoxicity in representative normal human brain while displaying enhanced replicative cytotoxicity in malignant glioma. These results have implications for the development of double-mutated CRAd vectors for enhanced GBM therapy.
Insights
Modified adenoviral vectors show promise for glioblastoma treatment. Ablating specific viral protein binding enhances cancer cell killing while sparing normal brain cells, improving therapeutic potential.
Area of Science:
- Oncolytic virology
- Cancer gene therapy
- Molecular virology
Background:
- Malignant glioma, particularly glioblastoma multiforme (GBM), is a highly aggressive brain tumor with poor patient prognosis.
- Current treatments for GBM offer limited efficacy.
- Conditionally replicating adenoviral vectors (CRAds) are being investigated as novel anti-cancer agents.
Purpose of the Study:
- To evaluate the oncolytic potency and specificity of CRAds with modified E1A protein binding capabilities.
- To reduce non-specific viral replication and cytotoxicity in normal cells.
- To enhance the anti-glioma efficacy of CRAds.
Main Methods:
- In vitro cytopathic effect assays.
- Quantitative PCR (qPCR) for viral replication analysis.
- Western blot and flow cytometry for cellular analysis.
Main Results:
- A double-mutated CRAd (Ad2/24CMV), with reduced E1A binding to p300/CPB and pRb, demonstrated superior anti-glioma efficacy.
- Ad2/24CMV showed attenuated replication and cytotoxicity in normal human brain cells compared to wild-type and single-mutated CRAds.
- Enhanced replicative cytotoxicity was observed specifically in malignant glioma cells.
Conclusions:
- Modifying E1A binding domains in CRAds improves oncolytic specificity and potency against GBM.
- Double-mutated CRAd vectors hold significant potential for developing enhanced GBM therapies.
- These findings pave the way for more targeted and effective virotherapy for malignant brain tumors.
